Results 151 to 160 of about 3,296 (215)

Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-blinded, Randomized Clinical Trial. [PDF]

Cancer Prev Res (Phila)
Morgan DR, Dominguez RL, Norwood DA, Montalvan-Sanchez EE, Piazuelo MB, Rodriguez-Murillo A, Delgado AG, Hernandez-Marrero J, Gonzalez-Pons M, Beasley TM, Cruz-Correa M, Wilson KT.   +11 more
europepmc   +1 more source

Identification of mitochondria-related feature genes for predicting type 2 diabetes mellitus using machine learning methods. [PDF]

Front Endocrinol (Lausanne)
Xuan X, Sun M, Hu D, Lu C.
europepmc   +1 more source

Targeted Therapies in Neuroblastoma: A History and a View to the Future. [PDF]

Cancers (Basel)
Shah N.
europepmc   +1 more source

Evaluating the effectiveness of large language models in abstract screening: a comparative analysis. [PDF]

Syst Rev
Li M, Sun J, Tan X.
europepmc   +1 more source

New and emerging therapies in type 1 diabetes mellitus. [PDF]

J Clin Invest
Herold KC, Evans-Molina C.
europepmc   +1 more source

Proportional rates models for multivariate panel count data. [PDF]

Biometrics
Xu Y, Zeng D, Lin DY.
europepmc   +1 more source

MTAP-Null Tumors: A Comprehensive Review on Synthetic Vulnerabilities and Therapeutic Strategies. [PDF]

Cells
Subramaniam B, Chong WC, Babaei A, Bornhorst M, Zhang C, Packer R, Nazarian J.   +6 more
europepmc   +1 more source

Deciphering the MYCN-driven metabolic microenvironment of neuroblastoma. [PDF]

Trends Mol Med
Wolf A, Leardini D, Li L, Masetti R, Lyssiotis CA, Barbieri E.   +5 more
europepmc   +1 more source

Thrombocytopenia and Vomiting Due to Difluoromethylornithine

Drug Intelligence & Clinical Pharmacy, 1987
A 32-year-old Haitian male with acquired immunodeficiency syndrome presented with complications of Isospora belli enteritis. Therapy with the investigational drug difluoromethylornithine was initiated. Severe thrombocytopenia, nausea, and vomiting developed during intravenous drug therapy and recurred upon rechallenge with low-dose oral ...
K J, Tietze, J A, Gaska, E M, Cosgrove
openaire   +3 more sources